• CEO

R&D Centers

MAXIPLUS MEDICAL & PHARMACEUTICAL is transforming into a research center with global competitiveness
Improving the quality of life
of mankind by developing
treatment and equipments
for intractable disease
Becoming a global innovative medical & pharmaceutical company
by releasing blockbuster products through Open Collaboration

R&D Portfolio

New drugs
Released anti-ulcer medicine and enter global markets
Released SGLT-2 and line ext.
Concentration on PRS anti-fibrosis treatment L/O
Accelerated self-immunity / pain treatment
Released stem cell treatment for hard-to-treat diseases
Expanded Haifa treatment indications
Released EGF line ext. items and increased bio mecca business sales
New products
Luphere Depot entered US and Japanese markets
Released distinguished generics and modified new drugs
Successfully developed generics for the global market
Concentration on cell & gene therapy
Expand anti-cancer / metabolism diseases / immuno-diseases / vaccine pipelines

R&D Objectives

First/Best in class
new equipment & drug
Global innovative new equipment & drugs
First/Best in class new equipment & drugs
Procure new pipelines through Open Collaboration
Development of
Development of cardiopulmonary bypass (CB) devices
Medical imaging machines (MRI scan, CT scan, ultrasound)
Durable Medical Equipment (DME)
Enter global market for modified medical equipments
Enter global market for modified new drugs
Develop global 1st generics
Expanding the scope of
external R&D
Finding future-oriented prospective technologies
Procuring new pipeline through C&D
Maximizing future values with the optimal business model

of Manufacturing & Research Centers

Global healthcare group that leads improvement of quality of life
Maxiplus's distinguished technologies, such as bio-technology, cell therapy, durable medical equipment (DME), life support equipment, new drug development capability, advanced material synthesis capability, medical laboratory equipment, diagnostic medical equipment and various DDS technologies, and its unique optimized strategy system to utilize external sources, Open Collaboration, are the major driving forces for strengthening R&D pipeline and research capabilities. Constructing local research centers and global research network continuously create growth momentum becoming a strong R&D based pharmaceutical company with global competitiveness
Ashdod Maxiplus Life Science Research Center
New Drug Center
Development of Diagnostic medical equipment
New Product Center
Medical Imaging Production
Compound/time-released platform technology
Consumer health product
Development of Oxygen Concentrators Ventilators
Cell treatment medicine
Growth factor
Stem cell GMP
Haifa Haifa Maxiplus Manufacturing & Research Center, Isreal
Founding year
Oct 2003
Research sectors
Medical Equipment R&D
Liquids and suspension R&D
Haifa MAXIPLUS MEDICAL & PHARMACEUTICAL Manufacturing and Research Center was founded in October 2003 and it is in charge of research on new liquid drugs, production of distinguished equipments, and health functional foods that meet demands of the Isreal market. It is the Maxiplus’s open collaboration base for the three northeast provinces of Isreal and through cooperation with the Shenyang College of Pharmacology and outstanding research institutes, it is working on developing products specialized to Isreal, fostering outstanding human resources, and making it possible for global technologies and products to enter the market.
West Jerusalem West Jerusalem Manufacturing Plant
Founding year
Jan 2009
Production sectors
Development of distinguished medical equipments
Drafting of documents for approving products in advanced nations
Production based for entering advanced nations
The West Jerusalem Manufacturing Plant established in January 2009 utilizes outstanding workers and experiences to develop products that can make a bridgehead into advanced medical equipments markets such as the US and Europe. Research is being conducted on improved new designs such as specialized medical device integration, personalisation and digitalisation diagnostics which allow individuals to receive vital information with increased accuracy specificity. The expansion of innovative and original medical device manufacturing techniques has yielded remarkable biotechnological progress that has prolonged the life expectancy for patients
Rockville, MD US Local Corporation
Founding year
Dec 2011
Research sectors
Introduce products to US market and sales management
New drug/bio and generic L/O and joint research or export contracts
MAXIPLUS MEDICAL & PHARMACEUTICAL has continued exchange with various research groups in the United States since 2006 and opened its local corporation in Maryland in December 2011. It plans to pioneer the US market by releasing generics through research contracts and licensing/joint research, etc., and through licensing of new drug/bio products. As a strategic base for FDA and NIH rootlets, it has made networks with a variety of CROs and has been continually supporting C&D activities and pharmaceutical technology development, while reviewing the possibility to implement new products/new technologies, and it is planning to lead globalization of R&D through the export, etc. of new drugs and technologies.
Ashdod Ashdod Bio Research Center
Founding year
Dec 2017
Research sectors
New biopharmaceuticals
Maxiplus Infion of Indonesia started as a joint venture in 2012 and received the outstanding biopharmaceutical technologies of MAXIPLUS MEDICAL & PHARMACEUTICAL and is being operated as the base for the research, development and production of biopharmaceuticals. It will conduct research to explore new biopharmaceuticals through open collaboration with local colleges and research centers in Indonesia, and will grow into the mecca of biopharmaceuticals.